Background Heart failure (HF) remains a significant cause of morbidity and mortality.
Multiple trials over the past several years have examined the effects of both angiotensin …

Objectives: The goal of the study was to assess the effects of angiotensin-converting enzyme
inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on the composite of …

Background There is insufficient evidence whether the benefit of adding angiotensin II
receptor blockers (ARBs) to angiotensin-converting enzyme (ACE) inhibitors outweighs the …

Background The association between angiotensin-converting enzyme inhibitors (ACEI) and
angiotensin receptor blockers (ARB) doses on outcomes in patients with heart failure (HF) …

Objectives To compare the efficacy and safety of angiotensin-converting enzyme inhibitors
(ACEis) and angiotensin receptor blockers (ARBs) in patients without heart failure. Patients …

Objectives: We sought to determine the effect of angiotensin receptor blockers (ARBs) on
mortality and hospitalization in patients with heart failure (HF). Background: There is …

Background: Heart failure (HF) with a preserved left ventricular (LV) ejection fraction (EF) is
the leading cause of hospitalization after 65 years of age. Individual randomized trials have …

Background and objective Angiotensin II type 1 receptor antagonists (ARBs) are widely used
as a substitute for angiotensin-converting enzyme inhibitors (ACEIs) to treat patients without …

Background: Trials evaluating angiotensin‐receptor blockers in heart failure (HF) have
shown inconsistent results. Objective: To evaluate the effect of angiotensin II (AII) receptor …

Context. Whether angiotensin converting‐enzyme inhibitors (ACEI) and angiotensin‐
receptor blockers (ARB) are useful in high risk patients without heart failure is unclear. We …